Sweet Profits Gushing From Boston Therapeutics (BTHE)

BTHE Stock, Boston Therapeutics Inc.Trading more than 5X their average volume (19,328) on Monday, the penny stock of Boston Therapeutics, Inc. (BTHE) is having one of the most incredible runs it’s seen all year. Looking to address unmet medical needs in diabetes with their SUGARDOWN®, an over-the-counter, natural dietary supplement product that helps people maintain healthy blood sugar levels, the Company’s recent U.S. Food and Drug Administration acceptance for their BTI-320 to treat Type 2 diabetes and weight management has traders taking notice. With a stated float of just 9 million, it’s no wonder how BTHE stock can move like it’s on a sugar rush from just a little bit of volume.

Coming SoonWant to crush the Markets and make profits of $624, $2,897, even $40,656?
HERE To Make Sure You Get All Of Our Penny Stock Alerts!

BTHE Stock Quote

Last 5 Trading Sessions:

Date Open High Low Last Change % Chg Volume
12/16/14 0.6800 0.7399 0.5500 0.6900 +0.0501 +7.83% 37,700
12/15/14 0.5000 0.6800 0.4900 0.6399 +0.1799 +39.11% 113,000
12/12/14 0.4400 0.4799 0.4000 0.4600 +0.0610 +15.29% 71,500
12/11/14 0.3000 0.4000 0.3000 0.3990 +0.1190 +42.50% 69,700
12/10/14 0.3400 0.3500 0.2401 0.2800 -0.0200 -6.67% 35,900

Boston Therapeutics, Inc., headquartered in Manchester, NH, is quickly becoming a leader in the field of complex carbohydrate chemistry. The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: BTI-320, is a non-systemic, non-toxic, therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes.

Beyond BTI-320, Boston Therapeutics has SUGARDOWN®, a complex carbohydrate-based dietary supplement that began its initial stage of market introduction after Advance Pharmaceutical agreed in June, 2011 to develop markets in Hong Kong, China and Macau. SUGARDOWN® has been the Company’s main source of revenues for the last few years and the news from last month that they are expanding their distribution to 12 additional countries in Asia, with a purchase order for 60,000 units to be tentatively shipped by the end of the Q1, 2015.

The Company made an announcement last week that the FDA accepted Boston Therapeutics’ Investigational New Drug Application for BTI-320 to treat Type 2 diabetes and weight management is really what kicked off the BTHE run. With Joslin Diabetes Center in Boston due to be the lead clinic where trials are due to begin in Q1, 2015, the primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (or HbA1c) and weight loss.

Unlike Orgenesis Inc. (ORGS), which is looking to kick off their revenue stream sometime down the road by changing the way the body reacts to low insulin levels, Boston Therapeutics is about to close out their 3rd year of revenue bookings from shipments of SUGARDOWN®. Revenue for the year ended December 31, 2013 was $323,412, an increase of $281,158 as compared to the year prior, but this year it looks like the Company will have trouble matching last year after booking just $186,711 for the 9 months ended September 30, 2014, $121,493 (65%) of which was booked in Q3.

Regardless of the slightly declining reveneus, the FDA acceptance has surely boosted interest in BTHE, even though it’s on a small scale. One or two trades for a couple thousand shares is enough to send BTHE stock in either direction. A climb from 0.23 to 0.74 (221%) in the course of 7 trading sessions, only one of which was with volume over 100,000 shares traded, should have every OTC trader’s attention.

Looking for the Best Penny Stocks to Buy?
HERE To Receive FREE Penny Stock Alerts

hot penny stocks, hot OTC stocks, best OTC stocks, best penny stocks

About BTHE Stock

Boston Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of carbohydrate-based therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases in a safe and efficient manner.

Click here to view the SEC filings for BTHE.
Click here to view the website for Boston Therapeutics, Inc., here for SugarDown.

Authorized: 200,000,000
Issued and Outstanding: 38,472,016

Bottom Line:

Uniquely, BTHE has very little debt on their books ($960,479) despite recording operating expenses of $3,945,599 for the first 9 months of 2014. With a reported public float of just 9,000,000 shares, BTHE stock remains one of the under-the-radar penny stocks that just can’t seem to stop it’s climb towards $1.

facebookTwitterStay Connected With Us: 

Subscribe Footer

[gravityform id=”6″ name=”Post” title=”false”]

We are 100% Anti-Spam and will never rent or sell your information.
Although many of our picks go up 100%, 200%, even 10,000%, there is always the chance a stock could move lower.

Last updated by at .